SASGO

SASGO is pleased to present this CPD programme to those who have received a copy of SAJGO, or read it online at www.sajgo.co.za, and are interested in gynaecological oncology and breast cancer.

To participate, please follow the instructions below and submit your answers by 28 March 2026.

To complete and submit this CPD activity go to www.mpconsulting.co.za

Note that from the 2nd of April 2024 MPC is now offering a comprehensive CPD compliance solution under their new brand as Vertice Software Solutions. This is an annual subscription offered to HCPs to:

- Gain access to all relevant CPD medical journals published on the **Sabinet African Journals Platform** with full functionality and seamless integration to support medical research.
- Complete CPD assessments for all accredited medical journals (excluding those associated with Association or Society Memberships) on the Vertice Software Solutions' system.
- Receive CPD Compliance Support services to HCPs requiring assistance with their CPD compliance status at the Health Professions Council of South Africa (HPCSA), where HCPs complete CPD assessments for Medical Journals. This support service is provided by Vertice Software Solutions.

To subscribe to this service, or more information please contact the Vertice support team support@vertice.software.

Thank you for your participation, we trust you have enjoyed the read!

Join SASGO and get a SAJGO journal subscription with 3 CEUs CPD programme per annum.

1. Which of the following is not a cervical screening method?
a. Pap smears
b. Visual Inspection with Acetic Acid (VIA)
c. Thermal ablation of the transformation zone
d. HPV testing
e. Colposcopy

2. Important reasons for poor uptake of cervical screening in low resource settings do not include:
a. Lack of knowledge in the community
b. Poor access to health care
c. Inadequate education of healthcare professionals
d. Distrust of healthcare workers by the community
e. Lack of cervical screening campaigns

3. Treatments for cervical pre-invasive lesions do not include:
a. LLETZ
b. Radical hysterectomy
c. Cold knife Cone biopsy
d. Thermal ablation
e. Laser conisation

4. Which is not an adverse effect of thermal ablation of the cervix?
a. Watery vaginal discharge
b. Pruritus vulvae
c. Vaginal bleeding
d. Abdominal cramps
e. Vaginal burns

5. One of these is not a risk factor for persistent trophoblastic disease:
a. Complete hydatidiform mole
b. Hyperthyroidism
c. Maternal age
d. Ethnic group
e. Previous hydatidiform mole

6. This biomarker is routinely measured when following up women with gestational trophoblastic neoplasia (GTN):
a. TSH
b. HPL
c. BHCG
d. LDH
e. CA125

7. Persistent trophoblastic disease is usually treated with:
a. Suction evacuation
b. Hysterectomy
c. Chemotherapy
d. Radiotherapy
e. Anti-D Immunoglobulin

8. In women with gestational trophoblastic neoplasia, the following is not an indication for hysterectomy:
a. Massive haemorrhage
b. Placental site trophoblastic tumour
c. Epithelioid trophoblastic tumour
d. Family completion
e. Poor response to chemotherapy

9. Routine management of women with stage 3 cervical cancer does not include:
a. Percutaneous nephrostomies
b. Chemoradiation
c. External beam radiation
d. Intracavitary brachytherapy
e. Best supportive care

10. HPV E6/E7 pathways lead to all except one of the following:
a. Downregulation of p53 and Rb
b. DNA methylation
c. Histone modification
d. Increased expression of oncoproteins
e. Carcinogenesis

11. Potential risk factors for invasive recurrence of a borderline ovarian tumour may not include:
a. Mucinous histology
b. Micropapillary variant of serous borderline tumour
c. Presence of microinvasion
d. BRCA positivity
e. Inadequate initial surgical staging

12. Multizonal HPV disease of the lower anogenital tract is commonly associated with which other medical comorbidity:
a. Diabetes mellitus
b. Tuberculosis
c. SLE
d. Other malignancies
e. HIV

I declare this is my own unguided work. Signature:..... Date: .....

2025 Accreditation number: MDB015/031/01/2025

Medical Practice Consulting:
Client Support Center: +27121117001
Office – Switchboard: +27121117000